The purpose of the current study was to examine the immune response of sheep given the Rift Valley Fever virus vaccination adjuvanted with Carbopol？. Fifteen sheep were divided into three groups of five each. The first group received the ALOH adjuvanted inactivated RVF vaccination. The second group received the carbopol adjuvanted inactivated RVF vaccination. In the third group, no immunizations were administered as a control. In order to evaluate the Cellular immune response and the humeral immune response, the generated vaccines were evaluated by measuring the levels of interleukin, interferon and antibody levels using the enzyme linked immunosorbant assay (ELISA) and serum neutralization test (SNT). The efficacy of the vaccines was assessed using the challenge test in mice. The findings showed that the Carbopol？ Adjuvanted inactivated RVF vaccine generated a potent immune response better than the traditionally produced ALOH adjuvanted vaccine.
References
[1]
WOAH (2023) Rift Valley Fever (Infection with Rift Valley Fever Virus). Terrestrial Manual 2023. Chapter: 3. 1. 20.
[2]
Kenawy, M.A., Abdel-Hamid, Y.M. and Beier, J.C. (2018) Rift Valley Fever in Egypt and Other African Countries: Historical Review, Recent Outbreaks and Possibility of Disease Occurrence in Egypt. ActaTropica, 181, 40-49. https://doi.org/10.1016/j.actatropica.2018.01.015
[3]
Look, M., Bandyopadhyay, A., Blum, J.S. and Fahmy, T.M. (2010) Application of Nanotechnologies for Improved Immune Response against Infectious Diseases in the Developing World. AdvancedDrugDeliveryReviews, 62, 378-393. https://doi.org/10.1016/j.addr.2009.11.011
[4]
Ibrahim, A.M. (2002) Improvement and Evaluation of Rift Valley Fever Vaccine. Ph.D. Thesis, Moshtohor, Zagazig University.
[5]
Facciolà, A., Visalli, G., Laganà, A. and Di Pietro, A. (2022) An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines, 10, Article 819. https://doi.org/10.3390/vaccines10050819
[6]
Ulanova, M., Tarkowski, A., Hahn-Zoric, M. and Hanson, L.Å. (2001) The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism. InfectionandImmunity, 69, 1151-1159. https://doi.org/10.1128/iai.69.2.1151-1159.2001
[7]
Cox, J.C. and Coulter, A.R. (1997) Adjuvants—A Classification and Review of Their Modes of Action. Vaccine, 15, 248-256. https://doi.org/10.1016/s0264-410x(96)00183-1
[8]
Confavreux, C., Suissa, S., Saddier, P., Bourdès, V. and Vukusic, S. (2001) Vaccinations and the Risk of Relapse in Multiple Sclerosis. NewEnglandJournalofMedicine, 344, 319-326. https://doi.org/10.1056/nejm200102013440501
[9]
Mair, K.H., Koinig, H., Gerner, W., Höhne, A., Bretthauer, J., Kroll, J.J., et al. (2015) Carbopol Improves the Early Cellular Immune Responses Induced by the Modified-Life Vaccine Ingelvac PRRS® MLV. VeterinaryMicrobiology, 176, 352-357. https://doi.org/10.1016/j.vetmic.2015.02.001
[10]
Mumford, J.A., Wilson, H., Hannant, D. and Jessett, D.M. (1994) Antigenicity and Immunogenicity of Equine Influenza Vaccines Containing a Carbomer Adjuvant. EpidemiologyandInfection, 112, 421-437. https://doi.org/10.1017/s0950268800057848
[11]
Vereecken, M., De Herdt, P., Ducatelle, R. and Haesebrouck, F. (2000) The Effect of Vaccination on the Course of an experimental Salmonellatyphimurium Infection in Racing Pigeons. AvianPathology, 29, 465-471. https://doi.org/10.1080/030794500750047225
[12]
Minke, J.M., Toulemonde, C.E., Dinic, S., Cozette, V., Cullinane, A. and Audonnet, J.C. (2007) Effective Priming of Foals Born to Immune Dams against Influenza by a Canarypox-Vectored Recombinant Influenza H3N8 Vaccine. JournalofComparativePathology, 137, S76-S80. https://doi.org/10.1016/j.jcpa.2007.04.016
[13]
Gualandi, G.L., Losio, N.M., Muratori, G. and Foni, E. (1988) The Ability by Different Preparations of Porcine Parvovirus to Enhance Humoral Immunity in Swine and Guinea Pigs. Microbiological, 11, 363-369.
[14]
Tollersrud, T., Nørstebø, P.E., Engvik, J.P., Andersen, S.R., Reitan, L.J. and Lund, A. (2002) Antibody Responses in Sheep Vaccinated against Staphylococcus aureus Mastitis: A Comparison of Two Experimental Vaccines Containing Different Adjuvants. VeterinaryResearchCommunications, 26, 587-600. https://doi.org/10.1023/a:1020960402112
[15]
Liu, I.K.M., Turner, J.W., Van Leeuwen, E.M.G., Flanagan, D.R., Hedrick, J.L., Murata, K., et al. (2005) Persistence of Anti-Zonae Pellucidae Antibodies Following a Single Inoculation of Porcine Zonae Pellucidae in the Domestic Equine. Reproduction, 129, 181-190. https://doi.org/10.1530/rep.1.00168
[16]
Hoogland, M., Opriessnig, T. and Halbur, P. (2006) Effects of Adjuvants on Porcine Circovirus Type 2-Associated Lesions. JournalofSwineHealthandProduction, 14, 133-139. https://doi.org/10.54846/jshap/453
[17]
Gartlan, K.H., Krashias, G., Wegmann, F., Hillson, W.R., Scherer, E.M., Greenberg, P.D., et al. (2016) Sterile Inflammation Induced by Carbopol Elicits Robust Adaptive Immune Responses in the Absence of Pathogen-Associated Molecular Patterns. Vaccine, 34, 2188-2196. https://doi.org/10.1016/j.vaccine.2016.03.025
[18]
Gelfi, J., Pappalardo, M., Claverys, C., Peralta, B. and Guérin, J. (2010) Safety and Efficacy of an Inactivated Carbopol-Adjuvanted Goose Haemorrhagic Polyomavirus Vaccine for Domestic Geese. AvianPathology, 39, 111-116. https://doi.org/10.1080/03079451003604647
[19]
Aly, N.I., El-Shamandy, O.A., Shendy, M.B., Warda, F. and Farouk, E.M. (2020) Efficacy of Using Carbopol as an Adjuvant for Tissue Culture Inactivated Rabies Vaccine. JournalofAppliedVeterinarySciences, 5, 103-107. https://doi.org/10.21608/javs.2020.103395
[20]
United States Pharmacopeia Convention Inc. (2022) NF Monographs. Carbomer 934p. Rockville, USP-NF, 1900-1911.
[21]
Gihan, K.M., Khodeir, M.H. and Megid, K.A. (1993) Studies on Liver Function in Cattle Vaccinated with Rinderpest and Rift Valley Fever Vaccines. Egyptian Veterinary Medical Association, 53, No. 3.
[22]
Rossiter, P.B., Jessett, D.M. and Taylor, W.P. (1985) Microneutralisation Systems for Use with Different Strains of Peste des Petits Ruminants Virus and Rinderpest Virus. TropicalAnimalHealthandProduction, 17, 75-81. https://doi.org/10.1007/bf02360775
[23]
Reed, L.J. and Muench, H. (1938) A Simple Method of Estimating Fifty Per Cent Endpoints. AmericanJournalofEpidemiology, 27, 493-497. https://doi.org/10.1093/oxfordjournals.aje.a118408
[24]
Blackburn, N.K. and Besselaar, T.G. (1991) A Study of the Effect of Chemical Inactivants on the Epitopes of Rift Valley Fever Virus Glycoproteins Using Monoclonal Antibodies. JournalofVirologicalMethods, 33, 367-374. https://doi.org/10.1016/0166-0934(91)90036-y
[25]
WOAH (2012) RVF. Chapter 2.1.15, 334-343.
[26]
El-Nimr, M.M. (1980) Studies on the Inactivated Vaccine against Rift Valley Fever. Ph. D. Thesis (Microbiology), Faculty of Veterinary Medicine, Assiut University.
[27]
Eman, M.S. (1995) Studies on Rift Valley Fever Vaccine Inactivated with Binary. Ph.D. Thesis (Microbiology), Faculty of Veterinary Medicine, Cairo University.
[28]
WOAH (2024) Tests for Sterility and Freedom from Contamination of Biological Materials Intended for Veterinary Use. Chapter 1.1.9.
[29]
WOAH (2018) RVF (Infection with Rift Valley Fever Virus). Chapter 3.1.18.
[30]
Voller, A., Bidewell, D. and Bartlett, A. (1976) Microplate Enzyme Immunoassay for Immunoassay for the Immunodiagnostic of Virus Infection. American Society for Microbiology, 506-512.
[31]
Eduard, K. (1985) Progress in Enzyme Immunoassays: Production of Reagents, Experimental Design and Interpretation. Bulletinofthe World Health Organization, 63, 793-811.
[32]
Randall, R., Binn, L.N. and Harrison, V.R. (1964) Immunization against Rift Valley Fever Virus: Studies on the Immunogenicity of Lyophilized Formalin-Inactivated Vaccine. TheJournalofImmunology, 93, 293-299. https://doi.org/10.4049/jimmunol.93.2.293
[33]
Gihan, K.M., Elian, K.A. and Eman, M.S. (1998) Studies on the Keeping Quality of Binary Inactivated Rift Valley Fever Vaccine. Assiut Veterinary Medical Journal, 39, 169-179.
[34]
Himeidan, Y. (2016) Rift Valley Fever: Current Challenges and Future Prospects. ResearchandReportsinTropicalMedicine, 7, 1-9. https://doi.org/10.2147/rrtm.s63520
[35]
Dungu, B., Lubisi, B.A. and Ikegami, T. (2018) Rift Valley Fever Vaccines: Current and Future Needs. CurrentOpinioninVirology, 29, 8-15. https://doi.org/10.1016/j.coviro.2018.02.001
[36]
Carter, D. and Reed, S.G. (2010) Role of Adjuvants in Modeling the Immune Response. CurrentOpinioninHIVandAIDS, 5, 409-413. https://doi.org/10.1097/coh.0b013e32833d2cdb
[37]
Shabana, W. and Abd EL-Sadek, A. (2021) Effect of Carbomer as an Adjuvant for Enhancement of Immune-Response against FMD Vaccine. JournalofAppliedVeterinarySciences, 6, 27-36.
